Primary Immunodeficiency Diseases clinical trials at UC Health
1 research study open to eligible people
open to eligible people ages 16 years and up
The purpose of the proposed study is to acquire additional data (including the assessment of anti-rHuPH20 antibodies) on the long-term safety of HYQVIA and to assess the prescribed treatment regimens and treatment administration in routine clinical practice.
at UC Irvine UCLA